Dlbcl clinical trials

Explore recruiting dlbcl clinical trials.

Recruiting dlbcl studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Dlbcl trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase I/II, multicenter study evaluating the feasibility, safety, and efficacy of point-of-care manufactured GLPG5101 (19CP02) in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma

Netherlands, Belgium, Finland

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Phase I/II, open label, multicenter study of rapcabtagene autoleucel in adult patients with CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

France, Spain, Germany, Austria, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)

Spain, Belgium, Bulgaria, Greece, Denmark, Slovakia +10 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Portugal, Hungary, Bulgaria, Poland, Czechia, Croatia +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multi-center single arm Phase II study to evaluate the safety and efficacy of genetically engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen receptor in subjects with relapsed and/or refractory diffuse large B cell lymphoma

Hungary, Croatia

Therapeutic exploratory (Phase II) EU CTIS Study details

A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation - CLLRT2

Austria, Germany, Denmark, Ireland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Dlbcl trials by city

Dlbcl in Toronto Dlbcl in Vancouver Dlbcl in Montreal Dlbcl in Calgary Dlbcl in Edmonton Dlbcl in Ottawa Dlbcl in Winnipeg Dlbcl in Quebec City Dlbcl in Hamilton Dlbcl in Kitchener Dlbcl in London Dlbcl in Halifax Dlbcl in New York Dlbcl in Los Angeles Dlbcl in Chicago Dlbcl in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease